Objective A single-nucleotide polymorphism of the gene coding for catechol-O-methyltransferase (COMT Val 158 Met) is associated with prefrontal-dependent task performance in schizophrenia. We evaluated the relationship of the COMT genotype with diagnostic status and cognitive performance in schizotypal personality disorder.
Introduction
Catecholamine neurotransmitter activity in the prefrontal cortex (PFC) exerts a strong modulatory influence over a range of cognitive functions in mammals, including humans (Berridge and Waterhouse, 2003; Robbins and Allain, 2003) . This includes the regulation of working memory by PFC dopaminergic activity (reviewed in Marie and Defer, 2003) . Extensive evidence suggests deficits in working memory and other PFC-mediated executive functions in schizophrenia (reviewed in Weinberger et al., 2001 ). This working memory deficit extends to the schizophrenia spectrum, as individuals with schizotypal personality disorder (SPD) exhibit milder deficits on visual (Farmer et al., 2000) , visuospatial (LeesRoitman et al., 2000) and verbal working memory tasks, including the Paced Auditory Serial Addition Test (PASAT) [see Siever et al. (2002) for a review]. The working memory deficit of SPD may partly reflect a PFC catecholamine deficit. Relatives of patients with schizophrenia, who themselves have SPD, show plasma homovanillic acid levels that are reduced compared with relatives with other personality disorders or no psychiatric diagnosis (Amin et al., 1999) . Plasma homovanillic acid levels are inversely related to deficit-like symptoms of SPD, which in turn are related to executive and PFCrelated functions (Siever and Davis, 2004) . A preliminary study of SPD patients found plasma homovanillic acid to be significantly inversely related to perseverative errors on the Wisconsin Card Sort Test (WCST) (Siever et al., 1993) , a problem-solving task that is highly dependent on PFC function and which also shows consistent deficits among patients with schizophrenia (Weinberger et al., 2001) . In addition, while SPD patients exhibit a deficit in visuospatial working memory relative to a non-schizophrenia spectrum personality disorder comparison group, they show a greater improvement than this comparison group after amphetamine administration (Kirrane et al., 2000) . These findings suggest that the working memory deficit and other executive dysfunctions of SPD may be partly mediated by reductions in PFC catecholamine activity.
In addition, episodic memory deficits are observed across the schizophrenia spectrum, including in SPD (reviewed in Siever and Davis, 2004) . The California Verbal Learning Test (CVLT) in particular has been employed to consistently demonstrate verbal learning and recall deficits in SPD (Voglmaier et al., 1997 Bergman et al., 1998; Mitropoulou et al., 2002) . While there is functional brain imaging evidence for the role of PFC in episodic memory (Gabrieli, 1998) , the delayed recall component of these tasks may be more temporal lobe-dependent (Squire et al., 2004) . It is unknown whether the deficits of SPD patients on these tasks are related to PFC or medial temporal lobe dysfunction (or both). In addition, the role of PFC dopamine in modulating encoding and retrieval processes remains unaddressed, both in healthy individuals and in the schizophrenia spectrum.
Recent investigation in the neurochemical modulation of PFC-mediated cognitive functions has emphasized the effects of variation in the catechol-O-methyltrasferase (COMT) gene (Winterer and Goldman, 2003) , which is associated with varying rates of dopamine degradation (Chen et al., 2004) with likely resulting effects on synaptic dopamine levels in PFC. Healthy adults homozygous for the low-activity Met allele make fewer WCST perseverative errors than those with at least one Val allele Malhotra et al., 2002) , and healthy children who are Met/Met homozygotes perform better on a modified Stroop Test (Diamond et al., 2004) . Other investigations, however, have not found clear benefits of Met/Met homozygosity for PFC-mediated cognitive function in healthy adults (Joober et al., 2002; Fossella et al., 2002; Gallinat et al., 2003; Tsai et al., 2003) .
Nevertheless, COMT genotype variation exerts effects on PFC-dependent task performance in schizophrenia. Met allele load is inversely related to WCST perseverative errors among patients with schizophrenia Joober et al., 2002) , accounting for approximately 4% of the variance in WCST performance . Nolan et al. (2004) found schizophrenic patients with the Met/Met genotype to exhibit better imitation learning acquisition, though worse reversal learning. The COMT genotype is also specifically associated with the working memory demands of N-Back performance (Goldberg et al., 2003) , with Met allele load associated with a more efficient neural response on this task, measured as hemodynamic activation of dorsolateral PFC and anterior cingulate cortex during task performance by functional magnetic resonance imaging . Bilder et al. (2002) , in another study on chronic schizophrenic patients, found the Met allele associated with the processing speed and attention domain of cognition (accounting for 11% of the variance), although not with other cognitive domains including executive and visuoperceptual functions, declarative verbal learning and memory, simple motor ability or global neurocognitive function. A study of 89 sibling pairs discordant for psychosis (Rosa et al., 2004 ) also found no significant association of the COMT genotype with WCST perseverative errors in the patient group, although they did find an association of Met allele load with fewer perseverative errors in the non-psychotic sibling group. It is presently unclear whether the discrepant findings in the literature represent differences in study design (such as varying racial distributions or statistical power), or underlying complexity in the relationships under study. This last possibility could be due to factors such as the inverted U-shaped curve relating cognitive performance to central catecholamine activity, or the activity of neurochemical systems other than dopamine (such as norepinephrine) that are also regulated by COMT activity [see Bilder et al. (2004) for a discussion). In any event, this growing literature provides clear evidence that functional variation in the COMT genotype has effects on PFC-dependent task performance in schizophrenia.
The relationship between the COMT genotype and cognition has been poorly addressed for disorders related to schizophrenia, such as SPD. SPD serves as a useful model for investigating the pathophysiology of schizophrenia, as SPD patients are over-represented among the families of schizophrenia patients, and exhibit symptoms related to both positive and negative symptoms of schizophrenia, yet are generally lacking in the effects of chronic antipsychotic exposure, institutionalization, general intelligence deficit and sustained functional decline (Siever and Davis, 2004) . A recent report of a large nonclinical sample of young Greek male military recruits showed COMT Val allele load to be associated with negative symptom and disorganization factors from the schizotypal personality questionnaire, but not with positive or paranoid factors, nor with performance on versions of the CPT, N-Back and antisaccade tasks (Stefanis et al., 2004) . The implications of these findings for the relationship between the COMT genotype and cognition in the schizophrenia spectrum, however, remain unclear, given the uncertain clinical status of these participants and the lack of data addressing the direct relationship between schizotypy and cognitive performance in this sample.
We undertook the present study to evaluate the role of COMT genotype variation in the performance of SPD patients on an executive function task (WCST) that shows COMT genotype effects in schizophrenia (cited above), and memory tasks that are partly prefrontal dependent (including working memory and episodic memory, each with verbal and visual measures). As outlined above, SPD is characterized by consistent deficits in PFC-dependent cognitive functions such as working memory and episodic memory. In addition, PFCdependent functions such as working memory and other executive functions are known to be regulated by COMT genotype variation. As of yet, however, there are no reports addressing the role of COMT genotype variation in the performance of these functions in patients with SPD. We hypothesized that patients with SPD would exhibit COMT genotype effects on cognition similar to those reported for patients with schizophrenia.
Methods

Study participants
Individuals were recruited for the schizotypal (SPD) and non-schizotypal personality disorder (NSPD) groups from the community, primarily by advertisement but also by referrals from mental health clinicians. Inclusion criteria included age more than 18 and less than 60 years, no recent psychotropic medication at time of study and no significant medical illness, including no history of neurological illness or head injury. Personality disorder patients were excluded if they had comorbid diagnoses of a primary psychotic disorder, bipolar affective disorder type I or current substance abuse or dependence. Most patients had never been treated with neuroleptic medication. Personality disorder patients underwent diagnostic assessment with the Structured Interview for the Diagnostic and Statistical Manual of Mental Health (DSM)-IV Personality Disorders (Pfohl et al., 1996) , although they were assigned diagnoses according to DSM-III-R, and the Structured Clinical Interview for DSM-IV Axis I (First et al., 1995) . Consensus diagnoses were arrived at with the assistance of an expert diagnostician; our interrater reliability using this procedure is adequate (k = 0.73 for the SPD diagnosis). Normal control (NC) participants were also recruited from the community by advertisement, with the same inclusion criteria. These participants were screened for psychiatric illness, assessed with the same structured diagnostic interviews if necessary, and excluded if they were determined to have any personal or family history of psychiatric illness.
The total original sample that had genotyping at the COMT Val 158 Met locus (n = 281) included 67 SPD, 154 NSPD and 60 NC participants. This full sample was evaluated for statistical analysis of genotype distribution by diagnostic category (see below). Of these 281 participants, we identified the largest racially homogeneous subsample that performed the neurocognitive battery in order to minimize the important problem of population stratification, which is prevalent in gene association studies (Cardon and Palmer, 2003) . This sample comprised 98 Caucasian individuals, including 23 SPD, 52 NSPD and 23 NC participants. Table 1 summarizes the resulting COMT genotype groups in this sample by demographic and clinical composition. Within the personality disorder cognition subsample, neither age, education or mean number of personality disorder diagnoses varied significantly by genotype (all P > 0.16 by t test) ( Table 1 ). In addition, sex ratio among the personality disorder cognition sample did not vary significantly by genotype (w 2 = 3.27, df = 2, P = 0.20). We nevertheless entered sex as an independent variable to all regression analyses of cognition in order to account for possible subtle effects of sexual dimorphism, as this has been found to moderate effects of COMT on various clinical measures (reviewed in Bilder et al., 2004) . Age and years of education were significantly less among the full personality disorder group than in the NC group by t test (Table 1) . We therefore entered age as a covariate in analyses of diagnostic group effects on cognition. We, however, did not enter education as a covariate, as this measure is a likely proxy for illness onset or severity, given the nearly ubiquitous finding of education decrement among SPD samples in studies of cognition [e.g. all reports cited in the Introduction, in which effect sizes on education between NC and SPD groups are in the 0.5 to Sample size in parentheses for the control group is number with each genotype (Val/Val, Val/Met, Met/Met, respectively). Personality disorder cluster totals are greater than the indicated total sample size for each group owing to comorbidity within individual participants. SPD, schizotypal personality disorder *P < 0.05 and **P < 0.01 in a t test comparing NC group to full personality disorder group. a Mean number of personality disorder diagnoses assigned to each participant, in each group. COMT, catechol-O-methyltransferase.
. Controlling (or matching) for education would probably represent an instance of the 'matching fallacy' emphasized in studies of schizophrenia (Meehl, 1970) . In addition, neither age nor education was associated with the COMT genotype across the full sample: age, F(2,95) = 1.11, P = 0.33; education, F(2,95) = 0.09, P = 0.91. Therefore, we did not enter these variables into the regression analyses examining COMT genotype effects on cognition.
Neurocognitive measures
Participants were evaluated on a brief neurocognitive battery assessing verbal and visual episodic and working memory, and an executive function task previously studied in detail for its association with genotypic variation in COMT. These included the following: WCST Perseverative Errors (Heaton, 1981) ; PASAT (Gronwall, 1977) with 50 trials at a 2-s rate, with total correct detections as the dependent variable; CVLT Long Delay Free Recall (Delis et al., 1987) Genotyping was performed by using the TaqMan assay (Applied Biosystems, ABI, Foster City, California, USA). The 5 0 -nuclease assay is performed by hybridizing two florescence-labeled allele-specific nucleotide probes at the single-nucleotide polymorphism locus and then genotyping is generated on the basis of the normalized fluorescence intensity. DNA sequences were obtained from GenBank (accession no.: Z26491). Primers and probes were designed by using Primer Express 2.0 (ABI). The sequences of primers and probes were as follows: forward primer, 5 0 -TCGAGATCAACCCCGACTGT-3 0 ; reverse primer, 5 0 -AACGGGTCAGGCATGCA-3 0 ; probe for Val allele, 5 0 -6FAM-CCTTGTCCTTCACGCCAGC-GA-3 0 -TAMRA and probe for Met allele, 5 0 -VIC-AC-CTTGTCCTTCATGCCAGCGA-3 0 -TAMRA. Primer and probe were synthesized by ABI.
The genotyping protocol has been described elsewhere (Xu et al., 2002) . Briefly, individual genotyping was measured by using ABI 7900 Sequence Detector with a 5 ml reaction volume and 1-3 ng DNA. Primer concentration was 900 nmol/l for each primer and 100 nmol/l concentration for each probe. Annealing temperature was 63.51C with 35 cycles. Genotyping was clustered by using SDS 2.2 software (ABI). Each cluster represented homozygous Val allele, heterozygous Val/Met, homozygous Met/Met allele and no DNA template control.
To estimate genotyping accuracy, we repeated the genotyping for the entire sample set twice. Only two genotype calls were mismatched among 643 total samples. The error rate was 0.2%. The highly accurate genotyping provided confidence for further analyses.
Statistical analysis
COMT Val/Met genotype distribution in the full sample (n = 281) was compared between SPD and other diagnostic groups by w 2 to evaluate whether there is an association between genotype and SPD. For the Caucasian sample who performed the neurocognitive testing (n = 98), the effect of diagnostic group membership on neurocognitive performance was evaluated by a preliminary multivariate analysis of covariate (MANCOVA), followed up where individual cognitive measures showed significant diagnostic group effects, with univariate analysis of variance (ANCOVA) comparing the SPD group separately with NSPD and NC groups. Age was entered as the covariate in each analysis. The effect of the COMT genotype on neurocognitive performance was assessed in a series of regression analyses. The regression model was created as follows. In the first step, sex, diagnosis and genotype were entered. Diagnostic group was entered as two variables: control vs. patient, and SPD vs. other (NC and NSPD), in order to distinguish the three diagnostic groups. Genotype was entered as two absence of two Val alleles), in order to distinguish the three genotype groups. In the second step, all pairwise diagnosis-by-genotype interaction terms were entered. The resulting variance in cognitive performance accounted for by the entire regression model is reported as a single r 2 value.
In addition, we evaluated the possible effects of psychiatric comorbidity on those cognitive measures that exhibited significant genotype effects. In post-hoc analyses, we identified axis I and personality disorder diagnoses with a frequency Z 10% and added each separately to the established regression model to determine whether these diagnoses contributed additional significant variance to cognitive performance. Significance for all tests was set at P < 0.05, two-tailed.
Results
Catechol-O-methyltransferase Val/Met allele distribution in the full sample (n = 281)
In the full sample, the observed distribution of genotypes was strongly consistent with the expectations of HardyWeinberg equilibrium (w 2 = 0.0002, df = 2, NS). The frequency of COMT Val/Met genotypes in the SPD group was as follows: Val/Val, 26; Val/Met, 30; Met/Met, 11. This distribution was not significantly different from that of the NC group (23, 29 and 8, respectively) (w 2 = 0.29, df = 2, P = 0.87) or the combined NC and NSPD group (69, 100 and 45, respectively) (w 2 = 1.24, df = 2, P = 0.54). This indicates that the COMT Val/Met genotype is not associated with the diagnostic status of SPD in this sample.
Association of diagnostic group membership with neurocognitive performance
The MANCOVA of the set of neurocognitive measures showed a significant effect of diagnostic group: F(10,150) = 2.03, P = 0.034. Among individual cognitive measures, significant effects of diagnostic group were observed for PASAT (F = 4.71, P = 0.012), CVLT (F = 5.87, P = 0.004) and Wechsler Memory Scale Visual Reproduction (WMS-VR) (F = 4.98, P = 0.009), with a trend effect on DOT (F = 2.52, P = 0.087) and no effect on WCST (F = 0.86, P = 0.43). Follow-up univariate ANCOVA on the cognitive measures showing significant diagnostic group effects in MANCOVA showed the SPD group to perform significantly worse than the NC group on PASAT [F(1,42) = 10.14, P = 0.003], CVLT [F(1,43) = 14.25, P < 0.0005] and WMS-VR [F(1,41) = 9.79, P = 0.003], and the SPD group to exhibit a trend toward worse performance than the NSPD group on PASAT [F(1,64) = 3.93, P = 0.052].
Association of catechol-O-methyltransferase genotype with neurocognitive performance
Regression analyses indicate a significant effect of COMT genotype on prefrontal-dependent task performance, with the Val/Val genotype associated with greater perseverative errors on WCST (t = 2.217, P = 0.029) and fewer correct on PASAT (t = -2.078, P = 0.041). These effects of genotype were independent of diagnosis. For illustrative purposes, group means are depicted for each diagnostic group by genotype combination for these two measures in Fig. 1 . Neither CVLT, WMS-VR or DOT showed effects of genotype (either as main effects or interactions with diagnosis) that met or approached significance in the regression models ( Table 2) .
Association of psychiatric comorbidity with significant catechol-O-methyltransferase genotype effects
The analyses of psychiatric comorbidity yielded the following results. On the WCST, significant effects were associated with dysthymic disorder (t = 2.02, P = 0.047), history of panic disorder with agoraphobia (t = 2.47, P = 0.015), current panic disorder (t = 2.33, P = 0.022), social phobia (t = 2.29, P = 0.025), PTSD history (t = 2.65, P = 0.010) and avoidant personality disorder (t = 2.32, P = 0.022). On the PASAT, significant effects were associated with major depression history (t = -2.39, P = 0.019) (although not with current major depression: t = -0.87, P = 0.39), and obsessive-compulsive personality disorder (t = 2.16, P = 0.034). The direction of this last effect indicates that obsessive-compulsive personality disorder was associated with better performance on the PASAT. In each of these cases, the effect of the COMT genotype on cognitive performance remained statistically significant in the regression model. No other comorbid axis I or personality disorder diagnoses contributed significant additional variance to performance on the neurocognitive tasks.
Discussion
In the present study, we found that variation in the COMT Val/Met genotype is not associated with the diagnosis of SPD. SPD was associated with cognitive impairment, as previously reported, including a performance worse than that of both patients with NSPD and healthy control individuals, on working and episodic memory tasks. In addition, the COMT Val/Val genotype made a significant independent contribution to worse performance on two prefrontal-dependent cognitive tasks, WCST and the PASAT. These effects were found across the entire participant sample.
The present findings suggest that functional variation in COMT activity affects the performance of PFC-mediated cognitive functions such as problem-solving and verbal working memory. These findings are consistent with the effects of the COMT genotype on WCST Joober et al., 2002) and verbal working memory COMT and cognition in schizotypy Minzenberg et al. 121 (Goldberg et al., 2003) deficits reported in patients with schizophrenia. This suggests that the role of COMT gene variation in the prefrontal cognitive deficits of schizophrenia extends to that of the schizophrenia spectrum. The results of the regression analyses indicate that this genotype variation is largely independent of cognitive effects associated with the diagnosis per se, suggesting additive effects in SPD. This appears to be consistent with studies of COMT effects on cognition in samples of schizophrenia patients and healthy controls, in which main effects of genotype are typically larger than genotype-by-diagnosis interactions Joober et al., 2002; Goldberg et al., 2003; Gallinat et al., 2003) . These studies, along with the present evidence, suggest that COMT genotype variation exerts effects on cognition independent of clinical status. Nevertheless, as discussed by Weinberger et al. (2001) , gene effects that are relatively modest, and comparable to those found among healthy individuals, may combine with other factors that impair prefrontal function in schizophrenia to have a substantial impact on residual function in these patients. Interestingly, the profiles of cognitive performance across COMT genotype appear consistent with the phenomenon of molecular heterosis, with the heterozygotes exhibiting the best performance level among the NC group, and the worst performance among the SPD group. This pattern has been increasingly uncovered in studies of gene polymorphisms (Comings and MacMurray, 2000) , and in the case of catecholaminergic genes, may be related to the inverted U-shaped curve that relates catecholamine activity to cognitive performance (c.f. Comings and MacMurray, 2000, Fig. 7 ). More generally, schizophrenia is understood to be a complex, polygenic disorder, and it appears likely that each symptom domain is itself the expression of multiple genes that may or may not interact in a complex manner. This pattern of pathophysiology probably also extends to the schizophrenia spectrum, given the similarity in findings from parallel studies of heritability, neurochemistry and cognition in SPD patients (Siever and Davis, 2004) . Remarkably, COMT genotype variation showed a greater effect on neurocognitive performance than the SPD diagnosis. To the extent that prefrontal-mediated neurocognitive function is associated with clinical symptomatology, this suggests that COMT genotype variation may exert strong effects on symptom expression in these patients.
In contrast, we found that the COMT genotype was not associated with performance on verbal and visual measures of episodic recall. This is consistent with the findings of a study of patients with schizophrenia, in which the COMT Val/Met genotype was not associated with episodic memory either at baseline or in response to antipsychotic medication (Weickert et al., 2004) . While these tasks may involve a degree of prefrontal dependence, particularly in implementing higher-order strategies to optimize encoding and retrieval (Gabrieli, 1998) , they are nevertheless more sensitive to disease in the medial temporal lobe than in PFC (Squire et al., 2004) . The lack of COMT gene-related effects on these tasks may therefore indicate the relatively greater role for COMT activity in regulating synaptic levels of dopamine in PFC compared with the medial temporal lobe. Alternatively, the important distinction between the WCST and PASAT and the remaining three tasks of this study may reside in the task demands of information updating and temporal indexing required in these first two tasks. These executive subprocesses may be more dopamine-dependent in general and therefore more sensitive to variations in synaptic dopamine associated with COMT genotype variation ). This would be consistent with findings of COMT genotype effects on similar tasks reported by other investigators Joober et al., 2002; Goldberg et al., 2003) . We also found no association of the COMT genotype with performance on the DOT, a task of visuospatial working memory. Our research group has found earlier that SPD patients exhibit a greater improvement in DOT performance upon amphetamine administration, compared with a heterogeneous personality disorder group (Kirrane et al., 2000) , suggesting that a basal catecholamine deficit may play a role in visuospatial working memory deficits. The present findings remain consistent with the notion of a basal deficit in catecholamine activity, perhaps in synthesis and/or release, rather than in varying rates of synaptic dopamine degradation, as a contributor to visuospatial working memory deficits in SPD.
The relationship of catecholamine activity to cognitive function has not otherwise been investigated for SPD or other personality disorder samples. The relationship of synaptic dopamine levels to cognitive function also appears to be complex, with biphasic or even triphasic effects of PFC dopamine on working memory, for example (Marie and Defer, 2003) . In the light of this observation, it may be that in a sample of patients with heterogeneous personality disorder diagnoses, there is great variation in basal levels of central catecholamine activity, with the consequence that decreased catecholamine degradation might lead to improvement in the cognitive performance of some individuals but impairment in others. It is also certainly possible that some of these cognitive functions are not sensitive to COMT activity. This could be due to either a role for catecholamine activity in certain cognitive functions that is relatively less important than that for other neurotransmitters, or alternatively that the primary process of catecholamine regulation is other than COMT-mediated degradation. Resolution of these issues is likely to require more homogeneous study samples, and probably additional studies addressing the cognitive effects of pharmacological manipulation of central monoamine levels, or neurochemical imaging studies of cognition, for example.
Study limitations
The sample size was modest for a study of this type, although it exceeded that in many other studies of COMT gene effects on cognition, and was very large for a study of patients with clinically diagnosed SPD. The subsamples of both SPD patients and NC participants were prohibitively small to confer adequate statistical power to test the effects of COMT genotype on cognition within these diagnostic groups. This may be the reason for the lack of diagnosis-by-genotype interaction effects found in the regression models of cognitive performance. As indicated above, the lack of interaction effects is, however, generally consistent with the foregoing schizophrenia literature. It remains untested whether COMT genotype effects are comparable among the diagnostic groups sampled in the present study. Resolution of this issue may require considerably larger sample sizes.
Conclusion
Functional allelic variation in the COMT genotype does not appear to be associated with a diagnosis of SPD. Nevertheless, COMT genotype variation is associated with performance on cognitive functions that are modulated by PFC dopamine systems, in SPD and other personality disorder patients as well as in healthy individuals. This variation may be partly responsible for the prefrontal-dependent cognitive deficits of patients with SPD, as they appear to be for patients with schizophrenia. For individuals with SPD or other personality disorders, other cognitive functions, such as those primarily mediated by the medial temporal lobe, may be less sensitive to levels of synaptic catecholamines that vary as a function of COMT activity. Future investigations should address issues of disorder specificity, and the role of interacting central monoaminergic systems in the expression of cognitive dysfunction in schizophrenia spectrum disorders.
